Breast Cancer Research and Treatment **24**: 265, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 24

Abe R 51
Amadori A 27
Amadori D 27
Arand G 241
Asaishi K 51
Attewell R 115
Ayme Y 139
Azzam H 241

Bae S-N 241
Baker WJ 43
Baldetorp B 115
Basset P 185
Behrens J 175
Bélanger A 127
Benz CC 85
Blank EW 103
Bocchiotti G 167
Borg Å 115
Boysen B 257
Brünner N 173,227,257

Carton M 139
Ceriani RL 103
Chambon P 185
Clarke R 227
Coronado E 85
Cremona M del C 1

Daban A 139
Danø K 173
DeGregorio MW 35,43
Delozier T 139

Emshoff VD 35,43
Enriori CL 1
Enriori PJ 1
Etindi RN 61
Ewers S-B 115

Fargeot P 139
Fernö M 115
Flamigni A 27
Frandsen TL 227,241
Frassineti GL 27
Frisell J 11
Fujita Y 51
Fujiwara K 51
Fumoleau P 139
Funahashi H 97

Garcia-Giralt E 139
Gazzanelli G 167
Goldman S 11
Gorins A 139
Graeff H 195
Guerin D 139
Guerin R 139

Hähnel E 71
Hähnel R 71
Harbeck N 195
Harvey J 71
Hirsig RJP 1
Höfler H 195
Höyhtyä M 209

Ikeda T 51
Iselius L 159
Ishida T 51
Iwase T 51

Jakesz R 17
Jänicke F 195
Johnson RM 85

Kasumi F 51
Kato I 51
Killander D 115
Koester SK 35,43
Koyama H 51

Labrie F 127
Lamport DTA 103
Långström E 115
Larsson C 159
Leonessa F 227
Lepage M 127
Li S 127
Lindblom A 159
Lippman J 227

Maenpaa JU 43
Magni E 27
Maillart P 139
Mannello F 167
Manni A 61
Martel J 61
Mauriac L 139
May-Levin F 139
McGarvey M 227
Mérand Y 127
Metz R 139
Milovanovic SR 147
Minor P 35
Miura S 51
Moroz C 17
Murata M 51

Namer M 139
Nanni O 27
Narita T 97
Nihei M 51
Nilsson B 11
Nordenskjöld M 159
Novelli JE 1

Olivier JP 139
Osborne CK 85

Pache L 195
Pavasant P 241
Peterson JA 103
Pommatau E 139
Pouillart P 139
Pujade-Lauraine E 139
Pyke C 209

Radulovic S 147
Ravdin PM 219
Reiner A 17
Reinerova M 17
Robbins P 71
Rømer J 257
Rosen HR 17
Rotstein S 159
Rouesse J 139

Saotome K 51
Sarup JC 85
Satoh Y 97
Savini S 27
Schally AV 147
Schemper M 17
Schmitt M 195
Scott GK 85
Serrou B 139
Shepard HM 85
Spang-Thomsen M 257
Sterrett G 71
Stierer M 17
Svec J 17
Szoke B 147

Takagi H 97
Tashiro H 51
Thompson EW 227,241
Torri J 241
Tripathy D 85
Troccoli T 167
Tryggvason K 209

Ulm K 195

Vitse M 139
Volpi A 27
von Rosen A 11

Warner E 75
Wiebe VJ 35,43
Wiege M 11
Wolf C 185
Wurz GT 35,43

Yamamoto H 51
Yokoe T 51

Zoli W 27
Zylberait D 139

Breast Cancer Research and Treatment **24**: 267-271, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 24

adhesion
see cell adhesion
adriamycin
see doxorubicin
aminoglutethimide
vs. MPA in 2d and 3d line endocrine therapy 139-145
androgens
controlled-release low-dose MPA in rat DMBA tumor model 127-137
androgens, conjugated
in breast cyst fluid 1-9
antiestrogen resistance
and metastasis in MCF-7 cell variants 227-239
in HER-2/*neu* transfected MCF-7 cells 85-95
potential mechanisms 227-239
antiestrogenic activity assay
effect of patient plasma on cell line 35-41
antiestrogens
see also tamoxifen, toremifene
apocrine cysts
and lipid-associated sialic acid levels 167-170

basement membrane invasion
Matrigel-based *in vitro* assays 241-255
benign breast disease
see cyst fluids
blood group oligosaccharides
and breast mucin epitope structures 103-113
breast epithelial mucin
epitopes detected by monoclonal antibody panels 103-113

c-erbB-2
see HER-2/*neu*
cadherin
see E-cadherin
cathepsin D
review of prognostic factor studies 219-226
vs. uPA and PAI-1 in prognosis 195-208
cation ratio (Na^+/K^+)
and classification of gross cystic disease 1-9, 167-170
cell adhesion
adhesion molecules in invasion and metastasis 175-184
in invasion and metastasis 173-174
chemosensitivity assay
potentiation of doxorubicin by lonidamine 27-34
chemotherapy, targeted
LHRH cytotoxic analogs, binding in human and MXT mouse tumors 147-158
collagenases
and penetration of basement membranes in invasion 247-250
collagenases, type IV
in tumor invasion and metastasis 209-218
cyst fluids in breast
review of biochemical studies 1-9
lipid-associated sialic acid levels 167-170
cytokines
and cell dissociation in invasion and metastasis 180-181

dehydroepiandrosterone sulfate (DHEA-S)
in breast cyst fluids, review 1-9
diet
in case-control study of breast cancer in Japan 51-59
differentiation markers
correlation with placental isoferritin p43 antigen 17-26
DMBA-induced rat mammary tumors
inhibition by controlled-release low-dose MPA 127-137
doxorubicin
potentiation by lonidamine 27-34
reversal of resistance by toremifene 43-49

drug resistance
HER-2/*neu* transfectants and cisplatin resistance 85-95
reversal by toremifene in ER– cells 43-49
see also antiestrogen resistance

E-cadherin
and cell adhesion in invasion and metastasis 175-184
gene structure and tumor expression 176-180
see also uvomorulin
EGF
in breast cyst fluids 1-9
electrolyte ratio (Na^+/K^+)
and classification of gross cystic disease 1-9, 167-170
endocrine therapy
antiestrogen resistance and metastasis in MCF-7 cell variants 227-239
LHRH cytotoxic analogs, binding in human and MXT mouse tumors 147-158
MPA vs. aminoglutethimide in 2d and 3d line therapy 139-145
epidermal growth factor
see EGF
estradiol
effects on phosphatidylinositol turnover in MCF-7 cells 61-70
estrogen receptor
and prognosis 203-206
and prognosis, with ploidy and S-phase 115-126
antiestrogen resistance and metastasis in MCF-7 cell variants 227-239
extracellular matrix
degradation by type IV collagenase in tumor invasion 209-218
degradation in invasion and metastasis 175-184
familial breast cancer
predominance of maternal inheritance 159-165
family history
in case-control study of breast cancer in Japan 51-59
ferritin
placental isoferritin p43 and differentiation features 17-26

fibroblast-derived factors
stromelysin-3 and invasive tumors 185-193
flow cytometry
ploidy and S-phase in a 10-year prognostic study 115-126

genetic labelling
lacZ transfectants for sensitive detection of micrometastases 257-263
genetics
predominance of maternal inheritance in familial breast cancer 159-165
glycolipids
lipid-associated sialic acid levels in breast cyst fluids 167-170
glycoproteins
breast mucin epitopes detected by monoclonal antibody panels 103-113
glycosylation
variants and breast mucin epitopes 103-113
gross cystic disease fluid proteins
review of biochemistry of breast cyst fluids 1-9

HER-2/*neu*
as a tumor marker in serum 97-102
tamoxifen resistance in transfectants 85-95
hereditary breast cancer
predominance of maternal inheritance 159-165
hormone independence
and metastasis in MCF-7 cell variants 227-239
hormone therapy
see endocrine therapy

IGF-I
in breast cyst fluids 1-9
inositol polyphosphates and kinases
in HER-2/*neu*-transfected, tamoxifen-resistant MCF-7 cells 85-95
insulin-like growth factors
see IGF-I
interval cancers in screening trials
overall survival vs. control cancers 11-16
invasion
Matrigel-based *in vitro* assays 241-255
invasion factors and models
special issue 173-263

Japanese breast cancer
case-control study of family, reproductive, and dietary factors 51-59

lactic acidosis
in metastatic breast cancer 75-79
lacZ transfectants
for detecting micrometastases in nude mouse model 257-263
laminin receptors
and cell attachment for invasion 228-229
attachment in invasion 245-246
lonidamine
potentiation of doxorubicin cytotoxicity 27-34
luteinizing hormone releasing hormone (LHRH)
cytotoxic analogs, binding in human and MXT mouse tumors 147-158

malignant progression
epithelial-mesenchymal transition 244-245
malignant progression
mechanisms in breast tumors 229
mammography
see screening
Matrigel
in assays of invasiveness 241-255
matrix metalloproteinases
see metalloproteinases
MCF-7 cells
antiestrogen resistant, metastatic variants 227-239
effects of TGFα and estradiol on phosphatidylinositol turnover 61-70
in bioassay of antiestrogenic activity of patient plasma 35-41
tamoxifen resistance in HER-2/*neu* transfectants 85-95
MDA-MB-231 cells
reversal of drug resistance by toremifene 43-49
medroxyprogesterone acetate (MPA)
controlled-release low-dose, inhibition of rat DMBA tumors 127-137
vs. aminoglutethimide in 2d and 3d line endocrine therapy 139-145
metalloproteinases
invasion of basement membranes 247-250
stromelysin-3 in fibroblastic cells surrounding invasive tumors 185-193
type IV collagenases in tumor invasion 209-218
metastasis
nude mouse model using lacZ transfectants for sensitive detection 257-263
metastasis factors and models
special issue 173-263
metastatic potential
possible mechanisms 233-234
micrometastases
detection in model system using lacZ transfectants 257-263
microspheres, poly[DL-lactide-co-glycolide]
for controlled-release of low-dose MPA in rat DMBA tumor model 127-137
monoclonal antibodies
panel detecting various breast mucin epitopes 103-113
motility factors
scatter factor in tumor cell dissociation and metastasis 180-181
mucin
see breast epithelial mucin

nude mice
in vivo model for metastases, strain dependence 257-263

obesity
in case-control study of breast cancer in Japan 51-59

PAI-1 (uPA inhibitor)
as a prognostic factor 195-208
paraneoplastic syndrome
cf. lactic acidosis in metastatic breast cancer 75-79
phosphatidylinositol turnover
effects of TGFα and estradiol in MCF-7 cells 61-70
placental isoferritin associated p43 antigen
and proliferation rate in cell lines 17-26
association with prognosis and differentiation features 17-26
ploidy
and prognosis, with ER and S-phase 115-126

prognostic factors
analysis, problems with cutpoints and subsetting 219-226
cathepsin D vs. uPA and PAI-1 195-208
cathepsin D, review of prognostic studies 219-226
ER, ploidy, and S-phase in a 10-year study 115-126
estrogen receptors, vs. uPA, PAI-1, cathepsin D 203-206
invasion and metastasis markers 173-174
placental isoferritin p43 and differentiation features 17-26
uPA and PAI-1 195-208
proteases
in invasion and metastasis 173-174
uPA, PAI-1, and cathepsin D in prognosis 195-208
see also metalloproteinases
pS2
expression in breast tissues by radioimmunoassay vs. Northern blots 71-74

reproductive history
in case-control study of breast cancer in Japan 51-59

S-phase
and prognosis, with ER and ploidy 115-126
scatter factor
in tumor cell dissociation and metastasis 180-181
screening trials
survival with interval vs. control cancers 11-16
serum markers
serum HER-2/*neu* (c-erbB-2) 97-102
sialic acid
in glycolipids of gross cystic disease fluids
special issue
invasion and metastasis factors 173-263
stroma-derived factors
stromelysin-3 and invasive tumors 185-193
stromelysin-3
gene structure and expression 186-189
in fibroblastic cells surrounding invasive tumors 185-193

tamoxifen
see also antiestrogens
tamoxifen activity assay
effect of patient plasma on cell line 35-41
metabolites by HPLC in patient plasma 35-41
tamoxifen resistance
in HER-2/*neu* transfected MCF-7 cells 85-95
MPA vs. aminoglutethimide in 2d and 3d line therapy 139-145
tandem repeat peptides
in breast mucin epitopes 103-113
TGFα
effects on phosphatidylinositol turnover in MCF-7 cells 61-70
TIMPs (tissue inhibitors of metalloproteinases)
and penetration of basement membranes in invasion 247-250
role in the invasive phenotype 209-218
toremifene
chemosensitizing effect for doxorubicin in ER– cells 43-49
see also antiestrogens
toremifene activity assay
effect of patient plasma on cell line 35-41
metabolites by HPLC in patient plasma 35-41
transforming growth factor alpha
see TGFα
tumor markers
serum HER-2/*neu* (c-erbB-2) 97-102

uPA inhibitor PAI-1
as a prognostic factor 195-208
urokinase
expression in fibroblastic cells surrounding invasive tumors 188-190
urokinase-type plasminogen activator (uPA)
as a prognostic factor 195-208
uvomorulin
loss in mesenchymal (metastatic) transition 241-255
see also E-cadherin

vascular endothelium
cell adhesion and invasion 181-182

vimentin expression
and mesenchymal (metastatic) transition 241-255

wound healing
stromelysin-3 expression during inflammatory phase 185-193

xenografts
nude mouse model for metastasis studies 257-263